Sign up Australia
Proactive Investors - Run By Investors For Investors

Mayne Pharma Group considering a "significant transaction"

Mayne Pharma Group considering a "significant transaction"

Mayne Pharma Group (ASX: MYX) has been granted a trading halt this morning as it considers a "significant transaction", with the company's shares placed in pre-open.

Mayne Pharma has not yet indicated what the transaction might entail, but the company said in late September that it was reviewing a number of strategic options to grow the business - and is considering a capital raising as part of this strategy.

Currently Mayne Pharma develops and manufactures proprietary and generic products, which it distributes directly or through distribution partners, while also providing contract manufacturing services.

FY12 sales revenue grew 10% to $51.9 million, EBITDA grew 81% to $14.3 million, with the reported net profit after tax up 265% to $6.2 million. Net operating cash increased 228% to $13.4 million.

The halt will last until the earlier of an announcement being made to the market, or the opening of trade on Monday 8th October.

 

Proactive Investors is a market leader in the investment news space, providing ASX “Small and Mid-cap” company news, research reports, StockTube videos and One2One Investor Forums.



Register here to be notified of future MYX Company articles
View full MYX profile

Mayne Pharma Group Timeline

Related Articles

Blood test
September 28 2016
The group has ambitions to strengthen its transatlantic focus through organic and strategic growth
Pills and the EU stars
July 19 2016
Alliance's swoop for Sinclair Healthcare Products in December helped it rack up first-half sales of £46.4mln
AZN2.jpg
November 16 2016
Silence is a platform technology company operating in a key area for the future of medicine - Canaccord Genuity.

© Proactive Investors 2016

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.